Insiders who reported open-market trades in the last 12 months at the companies Marshall Urist files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Terrance P. Coyne - $33.61M in RPRX purchases and sales in the last 12 months
Christopher Hite - $27.36M in RPRX purchases and sales in the last 12 months
George W. Lloyd - $9.57M in RPRX purchases and sales in the last 12 months
Gregory Norden - $161K in RPRX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Marshall Urist is a corporate insider, tracked as EVP, Research & Investments of Royalty Pharma plc (RPRX). InsiderAlpha holds 15 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Marshall Urist submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Marshall Urist been buying or selling stock?
Recorded transactions: 0 open-market purchases and 11 open-market sales ($7.01M) across all tracked filings.
Marshall Urist is EVP, Research & Investments of Royalty Pharma plc (RPRX). 15 SEC Form 4 filings on record going back to 2025, most recently on 5 October 2026. Most recent open-market trade: sold $236K of RPRX on 5 October 2026. Lifetime open-market sales: $7.01M.
Recent transactions
17
The latest 17 SEC Form 4 transactions reported by Marshall Urist.
InsiderAlpha's records for Marshall Urist go back to 2025: 15 primary Form 4 filings, an average of 7.5 per year. 11 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
